CD38-directed Cytolytic Antibody [EPC]

5853 reported adverse events

Drugs of this class: DARATUMUMAB DARATUMUMAB AND HYALURONIDASE-FIHJ (HUMAN RECOMBINANT) ISATUXIMAB ISATUXIMAB-IRFC

These side effects are most commonly reported by patients taking drugs of the CD38-directed Cytolytic Antibody [EPC] class:

# Side effect Count
0 PLASMA CELL MYELOMA 4384
1 OFF LABEL USE 4059
2 INFUSION RELATED REACTION 3006
3 NEUTROPENIA 2672
4 PNEUMONIA 2511
5 DIARRHOEA 2161
6 FATIGUE 2138
7 THROMBOCYTOPENIA 1791
8 DRUG INEFFECTIVE 1786
9 DEATH 1713
See all common reactions for CD38-directed Cytolytic Antibody [EPC]

Drugs of the CD38-directed Cytolytic Antibody [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 CROSSMATCH INCOMPATIBLE 45 0.7031
1 PLASMA CELL MYELOMA REFRACTORY 573 0.4283
2 PLASMA CELL LEUKAEMIA 128 0.2133
3 PRIMARY AMYLOIDOSIS 48 0.1868
4 MONOCLONAL IMMUNOGLOBULIN INCREASED 50 0.1748
5 LIGHT CHAIN ANALYSIS INCREASED 146 0.1413
6 PLASMACYTOMA 260 0.1396
7 PLASMA CELL MYELOMA RECURRENT 371 0.1141
8 PLASMA CELL MYELOMA 4384 0.1123
9 MONOCLONAL IMMUNOGLOBULIN PRESENT 71 0.0934
See all enriched reactions for CD38-directed Cytolytic Antibody [EPC]